CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome.
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
识别与CAR-T 细胞治疗患者长期疗效相关的新标志物是当前医学需求,尤其是在多发性骨髓瘤等疾病中。在本研究中,我们探讨了CAR密度对BCMA CAR-T 细胞功能的影响。功能和转录研究表明,CAR构建体高表达的CAR-T 细胞表现出增强的强直信号,伴有耗竭标志物上调以及体外细胞毒性增加,但体内BM浸润减少。利用scRNA-seq对基因调控网络进行表征,鉴定出在CAR High T细胞中上调的与激活和耗竭相关的调控子,为这些细胞功能差异背后的机制提供了见解。最后,我们证明,在多种血液系统恶性肿瘤中,接受富含CAR High T细胞的CAR-T 细胞产品治疗的患者临床反应显著更差。总之,我们的工作表明,CAR密度在CAR-T 活性中发挥重要作用,并对临床反应具有显著影响。
Identification of new markers associated with long-term efficacy in patients treated with CAR T cells is a current medical need, particularly in diseases such as multiple myeloma. In this study, we address the impact of CAR density on the functionality of BCMA CAR T cells. Functional and transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct show an increased tonic signaling with up-regulation of exhaustion markers and increased in vitro cytotoxicity but a decrease in in vivo BM infiltration.
Characterization of gene regulatory networks using scRNA-seq identified regulons associated to activation and exhaustion up-regulated in CAR High T cells, providing mechanistic insights behind differential functionality of these cells. Last, we demonstrate that patients treated with CAR T cell products enriched in CAR High T cells show a significantly worse clinical response in several hematological malignancies. In summary, our work demonstrates that CAR density plays an important role in CAR T activity with notable impact on clinical response.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。